2,000
Participants
Start Date
May 12, 2023
Primary Completion Date
April 30, 2024
Study Completion Date
April 30, 2026
Nirmatrelvir/ritonavir
Participants in the intervention arm will receive a standard 5-day treatment course Paxlovid (nirmatrelvir plus ritonavir) in addition to standard of care.
Placebo
Participants in the control arm will receive a 5-day course of placebo tablets, with the same appearance and quantity, in addition to standard of care.
RECRUITING
Haukeland University Hospital, Bergen
University of Bergen
OTHER
Oslo University Hospital
OTHER
University of Oslo
OTHER
St. Olavs Hospital
OTHER
Norwegian University of Science and Technology
OTHER
Haukeland University Hospital
OTHER